Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Articles|March 1, 2021
Pharmacy Times: Week of March 1
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Jesse McCullough on performance measures in pharmacy and leadership techniques for pharmacists.
- A new episode of the Pharmacy Focus podcast that focuses on prioritizing wellness as a pharmacist with Dr. Joanna Lewis, pharmacist and creator of the blog, The Pharmacist’s Guide.
- An article that shows more US adults than ever before reported receiving or planned to receive an influenza vaccination during the 2020-2021 flu season. The survey respondents came from the National Opinion Research Center’s AmeriSpeak panel, which uses a prescreened, nationally representative pool of participants to obtain rapid and projectable survey findings.
Advertisement
Related to this article
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
3
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
4
Medication Management: A Crucial Part of Healthy Aging
5